Spark Therapeutics (ONCE) Misses Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Spark Therapeutics Reports Third Quarter 2016 Financial Results and Recent Business Highlights
November 3, 2016 8:01 AM EDTCompletion of Biologics Licensing Application (BLA) submission for investigational candidate voretigene neparvovec on track for early 2017
Company makes progress across multiple programs, including its hemophilia franchise
PHILADELPHIA, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing investigational, potentially one-time, life-altering treatments, today announced financial results for the quarter ended Sept. 30, 2016 and updated investors on its progress.
During the last few months we have continued to execute on... More
